FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800745393> ?p ?o ?g. }

• W2800745393 endingPage "78" @default.
• W2800745393 startingPage "1" @default.
• W2800745393 abstract "Background Primary biliary cirrhosis (PBC) is an autoimmune liver disease, and 50% of patients with this disease experience fatigue. This is a debilitating symptom affecting quality of life and resulting in social isolation, which is highlighted by patients as a research priority. PBC is characterised immunologically by the presence of high-titre autoantibodies that are directed at the pyruvate dehydrogenase complex (PDC) and are highly effective at blocking its energy generation function. We hypothesised that if anti-PDC antibodies were a driver of fatigue through bioenergetic dysfunction, then the B-cell-targeting biological agent rituximab (MabThera ® , Roche Products Ltd, Welwyn Garden City, UK) might be a therapeutic option. Objective To assess whether or not rituximab safely improved moderate or severe fatigue in PBC patients. Design A Phase II, double-blind, randomised controlled trial comparing rituximab with placebo in fatigued PBC patients. Randomisation was conducted using a web-based system. Participants received two infusions on days 1 and 15 and were followed up at 3, 6, 9 and 12 months. Setting A single-centre UK study in Newcastle upon Tyne Hospitals NHS Foundation Trust. Participants Seventy-one participants aged ≥ 18 years with PBC and moderate or severe fatigue (score of > 33 on the PBC-40 fatigue domain) were screened. The PBC-40 questionnaire is a fully validated disease-specific health-related quality-of-life measure for use in patients with PBC. Fatigue, with a maximum score of 55, is one of its six domains. Fifty-seven participants were randomised to the trial, 55 of whom reached the primary end-point assessment. Intervention Participants were randomised in a 1 : 1 ratio to receive either rituximab (1000 mg) or a saline intravenous infusion (placebo) on days 1 and 15. The infusions were delivered in a double-blind manner using the same protocol. Main outcome measures The primary outcome measure was the PBC-40 fatigue domain at 3 months, assessed on an intention-to-treat basis. Secondary outcome measures included markers of bioenergetics function (anaerobic threshold and post-exercise muscle pH assessed using magnetic resonance imaging) and physical activity levels. Impact on biochemical markers of liver disease severity was assessed as an experimental outcome. Results Rituximab therapy was safe, with no serious adverse events linked to the drug. There was no statistically significant difference in fatigue score at 3 months between the rituximab and placebo arms [adjusted mean difference –0.9, 95% confidence interval (CI) –4.6 to 3.1]. However, improvement in fatigue was observed in both arms {mean score decreasing from 41.2 [standard deviation (SD) 5.5] to 36.2 (SD 8.4) in the rituximab arm and from 43.0 (SD 5.9) to 38.1 (SD 8.7) in the placebo arm}. There was little difference in any of the secondary outcomes between arms. However, anaerobic threshold improved significantly in the rituximab arm (adjusted mean difference at 3 months 1.41, 95% CI 0.03 to 2.80). No change in muscle bioenergetics characteristics was seen. A suggestive improvement in liver biochemistry was observed. Limitations Recruitment was lower than the original target, leading to a reduction in study power. A clinically significant placebo effect on PBC-40 fatigue scores was seen. Conclusions Rituximab is ineffective for the treatment of fatigue in unselected PBC patients despite metabolic modulation through improvement of anaerobic threshold. Future work Results from the trial demonstrate that metabolic effect of rituximab is not translated into clinical benefit. This will help to guide us to design future trials and when looking at completely different targets. Trial registration Current Controlled Trials ISRCTN03978701, ClinicalTrials.gov identifier NCT02376335 and EudraCT number 2012-000145-12. Funding This project was funded by the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme and will be published in full in Efficacy and Mechanism Evaluation ; Vol. 5, No. 2. See the NIHR Journals Library website for further project information. Additional funding was received from the Medical Research Council and a Department of Health and Social Care subvention." @default.
• W2800745393 created "2018-05-17" @default.
• W2800745393 creator A5000136849 @default.
• W2800745393 creator A5010325069 @default.
• W2800745393 creator A5010897540 @default.
• W2800745393 creator A5013990984 @default.
• W2800745393 creator A5047386786 @default.
• W2800745393 creator A5049443644 @default.
• W2800745393 creator A5050207691 @default.
• W2800745393 creator A5055495487 @default.
• W2800745393 creator A5069724066 @default.
• W2800745393 creator A5072303874 @default.
• W2800745393 creator A5078222146 @default.
• W2800745393 creator A5082915677 @default.
• W2800745393 creator A5090664198 @default.
• W2800745393 date "2018-04-01" @default.
• W2800745393 modified "2023-10-17" @default.
• W2800745393 title "Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial" @default.
• W2800745393 cites W118946960 @default.
• W2800745393 cites W131615448 @default.
• W2800745393 cites W1584416327 @default.
• W2800745393 cites W1598565601 @default.
• W2800745393 cites W1926762970 @default.
• W2800745393 cites W1964782374 @default.
• W2800745393 cites W1965412899 @default.
• W2800745393 cites W1965928933 @default.
• W2800745393 cites W1966382491 @default.
• W2800745393 cites W1967697261 @default.
• W2800745393 cites W1970449031 @default.
• W2800745393 cites W1978348205 @default.
• W2800745393 cites W1983127329 @default.
• W2800745393 cites W1987523828 @default.
• W2800745393 cites W1988536734 @default.
• W2800745393 cites W1991543228 @default.
• W2800745393 cites W1992780055 @default.
• W2800745393 cites W1994968614 @default.
• W2800745393 cites W2001176512 @default.
• W2800745393 cites W2012421341 @default.
• W2800745393 cites W2014533756 @default.
• W2800745393 cites W2016934176 @default.
• W2800745393 cites W2032058959 @default.
• W2800745393 cites W2033549902 @default.
• W2800745393 cites W2037710820 @default.
• W2800745393 cites W2047731573 @default.
• W2800745393 cites W2054440991 @default.
• W2800745393 cites W2054664696 @default.
• W2800745393 cites W2061868451 @default.
• W2800745393 cites W2063975050 @default.
• W2800745393 cites W2066874389 @default.
• W2800745393 cites W2070097736 @default.
• W2800745393 cites W2071394537 @default.
• W2800745393 cites W2077249205 @default.
• W2800745393 cites W2087469786 @default.
• W2800745393 cites W2087835721 @default.
• W2800745393 cites W2088111259 @default.
• W2800745393 cites W2089194680 @default.
• W2800745393 cites W2089526803 @default.
• W2800745393 cites W2093292173 @default.
• W2800745393 cites W2112534462 @default.
• W2800745393 cites W2126908341 @default.
• W2800745393 cites W2127182991 @default.
• W2800745393 cites W2131379299 @default.
• W2800745393 cites W2134836501 @default.
• W2800745393 cites W2138658411 @default.
• W2800745393 cites W2141276184 @default.
• W2800745393 cites W2141313006 @default.
• W2800745393 cites W2142021330 @default.
• W2800745393 cites W2157448436 @default.
• W2800745393 cites W2160783920 @default.
• W2800745393 cites W2162465435 @default.
• W2800745393 cites W2163859323 @default.
• W2800745393 cites W2166281097 @default.
• W2800745393 cites W2169509566 @default.
• W2800745393 cites W2171001437 @default.
• W2800745393 cites W2175544588 @default.
• W2800745393 cites W2324587274 @default.
• W2800745393 cites W2518389324 @default.
• W2800745393 cites W2522624190 @default.
• W2800745393 cites W2586480777 @default.
• W2800745393 cites W2786456523 @default.
• W2800745393 cites W4295008070 @default.
• W2800745393 doi "https://doi.org/10.3310/eme05020" @default.
• W2800745393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29733563" @default.
• W2800745393 hasPublicationYear "2018" @default.
• W2800745393 type Work @default.
• W2800745393 sameAs 2800745393 @default.
• W2800745393 citedByCount "8" @default.
• W2800745393 countsByYear W28007453932018 @default.
• W2800745393 countsByYear W28007453932019 @default.
• W2800745393 countsByYear W28007453932020 @default.
• W2800745393 countsByYear W28007453932022 @default.
• W2800745393 countsByYear W28007453932023 @default.
• W2800745393 crossrefType "journal-article" @default.
• W2800745393 hasAuthorship W2800745393A5000136849 @default.
• W2800745393 hasAuthorship W2800745393A5010325069 @default.
• W2800745393 hasAuthorship W2800745393A5010897540 @default.
• W2800745393 hasAuthorship W2800745393A5013990984 @default.
• W2800745393 hasAuthorship W2800745393A5047386786 @default.

• next